Objective  To observe the effect of repetitive transcranial magnetic stimulation (rTMS) combined with amisulpride in the treatment of schizophrenia and its influence on cognitive function.

Methods  A total of 100 schizophrenia patients were enrolled as study objects, and they were randomly divided into study group and control group, with 50 patients in each group. The control group was treated with amsulpiride, and the study group was treated with amsulpiride combined with rTMS. The clinical symptom score, therapeutic effect and cognitive function score of the two groups were compared.

Results  Before treatment, there was no significant difference in clinical symptom score between the two groups (P>0.05). After treatment, the general psychopathological score, positive symptom score, and negative symptom score of the study group were(30.13±1.23), (12.31±2.01), (17.91±4.15), which were lower than (33.17±2.15), (14.31±1.33), (20.31±3.17), respectively in the control group (P < 0.05). The total effective rate of the study group was 96.00% (48/50), which was higher than 68.00% (34/50) of the control group, and the difference was statistically significant (P < 0.05). Before treatment, there was no significant difference in cognitive function score between the two groups (P>0.05). After treatment, the item scores of all dimensions of cognitive function and total score in the study group were higher than those in the control group, and the differences were statistically significant (P < 0.05 or P < 0.01).

Conclusion  In the treatment of schizophrenia patients, rTMS combined with amisulpride can improve cognitive function and therapeutic effect, and relieve mental symptoms compared with amisulpride treatment alone.